On 6 November 2018, Lonza is hosting a free 60-minute webinar presenting a new approach to Electronic Batch Records (EBR) and demonstrating how Lonza’s MODA™ Execution System is designed to address the data management challenges facing biopharmaceutical manufacturers.
The bioscience industry is under increasing pressure to meet a rapid growth in demand, keep pace with ever-changing technologies and fulfill growing requirements for speed and efficiency. To address these challenges successfully, biopharmaceutical manufacturers need to consider electronic data as an integral part of the production workflow and not as the result of it.
Titled “Electronic Batch Records: An Innovative, Agile and Affordable Approach,” the webinar will be presented by Jeremy Tanner, Informatics Sales and Business Development Specialist at Lonza Bioscience Solutions. During the webinar he will discuss:
- How adopting a “follow-the-workflow” approach will overcome the process inefficiencies generated by quality and production silos
- What the benefits are of building flexibility and repeatability into an EBR that aligns with the ability to implement improvements as production and testing processes evolve
- Why Lonza has developed an EBR for semi-automated/non-automated processes and why manufacturing execution systems are not always the best option
Anyone interested in attending the webinar can register here.
Further information can be found on the MODA™ product page. By registering interest in the webinar, participants will also receive a link once the webinar is available to view “on demand” via the Lonza website.
More information about Lonza’s upcoming webinars is available here: www.lonza.com/webinars.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer’s healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel™ acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com
